Literature DB >> 25414429

Pneumonectomy for benign disease: indications and postoperative outcomes, a nationwide study.

Caroline Rivera1, Alex Arame2, Ciprian Pricopi2, Marc Riquet2, Giuseppe Mangiameli2, Mahdi Abdennadher2, Marcel Dahan3, Françoise Le Pimpec Barthes2.   

Abstract

OBJECTIVES: Pneumonectomy for benign disease is rare but is thought to have a higher more postoperative morbidity and mortality than when performed for lung cancer. We questioned this by assessing and analysing indications and postoperative outcomes of patients who underwent this type of resection.
METHODS: We used Epithor, the French national thoracic database including 91 public and private institutions with more than 220 000 procedures. We prospectively collected data of 5975 patients who underwent pneumonectomy between January 2003 and June 2013. The 321 patients (5.4%) who underwent pneumonectomy (n = 201) or completion pneumonectomy (n = 120) for benign disease were compared with those treated for malignant disease.
RESULTS: The patients' mean age was 55.2 years (53.5; 56.8) for benign indications vs 61.6 years (61.4; 61.9) for malignant disease; the sex ratio was 1.8 (207 males) and 4 (4543 males), respectively; 53% of patients (n = 169) had an American Society of Anesthesiologist (ASA) score of ≥3 vs 29% (n = 1598) for malignant disease. For benign disease, most frequent indications were infection or abscess (n = 114, 37.1%), post-tuberculosis destroyed lung (n = 47, 15.3%), aspergillosis or aspergilloma (n = 33, 10.7%), bronchiectasis (n = 41, 13.3%), haemorrhage (n = 26, 8.5%) and benign tumour (n = 20, 6.5%). Complications occurred in 53% (n = 170) of patients and the postoperative in-hospital mortality rate was 22.1% (n = 71). These results were significantly worse than those for malignant indications: 38.9% (n = 2198) of morbidity (P < 0.0001) and 5.1% (n = 288) of in-hospital mortality (P < 0.0001). For benign disease, there was no difference in fistula formation regarding side (P = 0.07) or type of resection (P = 0.6). Morbidity was higher for completion pneumonectomy: 62.5 vs 47.3% (P = 0.008). Mortality was significantly higher in case of resection for infection or abscess (P = 0.01) and for haemorrhage (P = 0.002). Emergency procedures were associated with worse postoperative outcomes (P < 0.0001).
CONCLUSIONS: Pneumonectomy for benign disease achieves cure with very high levels of morbidity and mortality. This type of surgical treatment should be considered as a salvage procedure.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Benign; Database; Morbidity; Mortality; Pneumonectomy

Mesh:

Year:  2014        PMID: 25414429     DOI: 10.1093/ejcts/ezu439

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Who Needs to Be Allocated in ICU after Thoracic Surgery? An Observational Study.

Authors:  Liana Pinheiro; Ilka Lopes Santoro; Sonia Maria Faresin
Journal:  Can Respir J       Date:  2016-07-17       Impact factor: 2.409

2.  Esophageal Balloon-Directed Ventilator Management for Postpneumonectomy Acute Respiratory Distress Syndrome.

Authors:  Eric Sy; Jagadish Rao; Sherma Zacharias; Juan J Ronco; James S Lee
Journal:  Case Rep Crit Care       Date:  2021-01-15

3.  The technique of stump closure has no impact on post-pneumonectomy bronchopleural fistula in the non-small cell lung cancer-a cross-sectional study.

Authors:  Piotr Skrzypczak; Magdalena Roszak; Mariusz Kasprzyk; Wojciech Dyszkiewicz; Mikołaj Kamiński; Piotr Gabryel; Cezary Piwkowski
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

4.  Factors affecting complication rates of pneumonectomy in destroyed lung.

Authors:  Aysun Kosif Mısırlıoğlu; Serkan Bayram; Hakan Kıral; Meltem Çoban Ağca; Fatma Tokgöz Akyıl; Levent Alpay; Volkan Baysungur; İrfan Yalçınkaya
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-04-30       Impact factor: 0.332

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.